FDA Clears Ravulizumab for Atypical Hemolytic Uremic Syndrome FDA Clears Ravulizumab for Atypical Hemolytic Uremic Syndrome

At 26 weeks, complete thrombotic microangiopathy (TMA) response was achieved in 54% of adults and 71% of children treated with the long-acting C5 complement inhibitor.FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Nephrology News Alert Source Type: news